What is the approximate cost of a full romosozumab course in the US?

The wholesale acquisition cost is roughly $22,500 for 12 monthly doses (two 105 mg prefilled syringes per dose). Net prices after rebates typically run 20% to 40% lower, per ICER analyses.

Is romosozumab cost-effective compared to alendronate?

In high-risk patients matching the ARCH trial profile (T-score near -3.0 with prior fracture), published models estimate ICERs of $78,000 to $147,000 per QALY depending on price assumptions. At net prices and in very high-risk subgroups, the drug falls within commonly cited willingness-to-pay thresholds.

Does Medicare cover romosozumab?

Medicare Part B covers romosozumab as a physician-administered injectable. Most plans require prior authorization documenting low T-scores, prior fracture or bisphosphonate failure, and cardiovascular clearance per the boxed warning on the Evenity label.

Why does patient selection matter so much for cost-effectiveness?

The absolute fracture risk reduction is larger in patients with lower T-scores and prior fractures. Since drug cost is fixed, higher baseline risk means more fractures prevented per dollar spent. Models show the ICER roughly doubles when moving from very high-risk to moderate-risk patients.

How does the ARCH cardiovascular signal affect economic modeling?

The ARCH trial showed a numerical excess of major cardiovascular events with romosozumab (2.5% vs. 1.9%). If confirmed as causal, models would need to add cardiovascular event costs, worsening the ICER. Current models either exclude or conservatively include this cost.

What is the cost per fracture prevented with romosozumab?

Based on ARCH data, the NNT to prevent one vertebral fracture over 24 months was approximately 12. At WAC, that translates to roughly $270,000 in drug cost per vertebral fracture prevented. At net price, this drops closer to $180,000.

How do international cost-effectiveness results compare to the US?

European and Japanese models generally produce more favorable ICERs due to lower drug prices and higher assigned costs for fracture-related long-term care. Swedish analyses found romosozumab cost-effective at ~€40,000/QALY in high-risk women.

Do guidelines recommend romosozumab based on cost-effectiveness?

The Endocrine Society and AACE recommend romosozumab for very high fracture risk. These recommendations are based primarily on efficacy data from the ARCH trial, though economic considerations support restricting use to the highest-risk patients where value is strongest.

Does the romosozumab-to-alendronate sequence affect cost models?

Yes. All major models follow the ARCH design of transitioning to alendronate (generic, low-cost) after romosozumab. Switching to denosumab instead adds ongoing biologic expense that would worsen the ICER.

What would make romosozumab more cost-effective in the future?

Three factors would improve the ICER: lower net drug price (biosimilar competition is years away), better tools for selecting patients most likely to fracture, and longer follow-up data confirming sustained fracture reduction beyond the trial's 33-month window.

ARCH Cost, Cost-Effectiveness, and Health-Economic Implications

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for ARCH Cost, Cost-Effectiveness, and Health-Economic Implications Image: HealthRX.com clinical image

At a glance

| Parameter | Detail | |---|---| | Trial | ARCH (Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk) | | N | 4,093 postmenopausal women | | Intervention | Romosozumab 210 mg SC monthly x 12 months, then alendronate | | Comparator | Alendronate 70 mg weekly throughout | | Duration | Median 33 months | | Primary endpoint | New vertebral fracture at 24 months | | Key result | 48% relative risk reduction in new vertebral fractures vs alendronate (Saag et al., NEJM 2017) |

The Clinical Foundation for Economic Modeling

The ARCH trial was the first phase 3 study to show a bone-forming agent could reduce fracture risk compared to an active bisphosphonate rather than placebo. Romosozumab reduced new vertebral fractures by 48% at 24 months and cut clinical fractures (nonvertebral plus symptomatic vertebral) by 27% over the open-label period. Hip fracture incidence fell by 38%, though this secondary endpoint did not reach statistical significance until a later time point in the extended analysis.

These absolute risk reductions form the input variables for every subsequent cost-effectiveness model. A 48% relative reduction against an already-effective comparator translates to smaller absolute differences than one might assume, because alendronate itself reduces vertebral fractures by roughly 44% versus placebo. That layered-benefit math matters enormously when modeling incremental cost per fracture prevented.

The trial enrolled women with a mean age of 74 years, T-scores averaging -2.96 at the total hip, and high prior fracture prevalence. Per the Evenity prescribing information, the FDA indication specifically targets postmenopausal women at high fracture risk, a population selection that directly shapes who benefits enough to justify the price.

List Price vs. Net Price: The Numbers That Matter

Romosozumab's wholesale acquisition cost (WAC) in the United States sits near $22,500 for the 12-month course (two 105 mg prefilled syringes per monthly dose). Generic alendronate costs approximately $10 to $30 per month. The gap is stark: roughly $22,000 in incremental drug cost over the anabolic phase alone.

However, WAC overstates what most payers actually spend. Manufacturer rebates, 340B pricing for safety-net hospitals, and Part D negotiated rates reduce the effective net price. Estimates from ICER's 2019 review of romosozumab assumed net prices 20% to 40% below WAC in their base-case analyses. Even at a 30% discount, the incremental cost of the romosozumab-first sequence exceeds $15,000 relative to alendronate monotherapy, a figure that must be weighed against avoided fractures, hospitalizations, and long-term care.

Published Cost-Effectiveness Models

The US Perspective

Multiple groups have modeled the value of romosozumab using ARCH data as the efficacy input. The general approach follows a Markov microsimulation: patients cycle through health states (no fracture, vertebral fracture, hip fracture, other nonvertebral fracture, post-fracture, death) with transition probabilities drawn from the ARCH primary publication and background epidemiologic data.

A US-focused analysis by Parthan et al. (2019) modeled a romosozumab-to-alendronate sequence versus alendronate alone in women aged 70 and older with T-scores at or below -2.5 and prior fracture. Base-case results yielded an incremental cost-effectiveness ratio (ICER) of approximately $147,000 per QALY gained at WAC. Sensitivity analyses showed this dropped below $100,000/QALY at net prices approaching a 40% discount and in subgroups with baseline T-scores at or below -3.0. The model was sensitive to three inputs above all others: drug price, time horizon, and hip fracture incidence.

| Scenario | ICER ($/QALY) | |---|---| | Base case (WAC, age 70+, T-score ≤ -2.5) | ~$147,000 | | Net price (30% discount) | ~$108,000 | | Very high risk (T-score ≤ -3.0 + prior hip fracture) | ~$78,000 | | Moderate risk (T-score -2.5, no prior fracture) | >$200,000 |

European and International Models

Söreskog et al. (2021) applied Swedish cost data to ARCH efficacy inputs and reported an ICER of approximately SEK 450,000 (~€40,000) per QALY in high-risk women, well within Sweden's informal threshold. The model used a lifetime horizon and included costs of nursing home placement following hip fracture, a major cost driver in Scandinavian systems.

Hagino et al. (2019) modeled the Japanese setting and found romosozumab cost-effective at ¥5 million/QALY in patients matching the ARCH risk profile. The Japanese reimbursement price for romosozumab is considerably lower than the US WAC, explaining much of the difference.

These cross-country comparisons highlight a consistent pattern: romosozumab's economic profile improves when (a) the drug price is lower, (b) the patient's fracture risk is higher, and (c) the health system assigns greater cost to downstream fracture care.

What Drives the ICER Up or Down

Patient Selection Is Everything

The single most important variable in every published model is baseline fracture risk. Women who match the ARCH enrollment criteria, T-score near -3.0 with prevalent vertebral fracture, generate enough avoided fractures over a lifetime horizon to bring the ICER into a range most payers consider acceptable. Extending eligibility to moderate-risk patients (T-score -2.5, no prior fracture) roughly doubles the ICER because the absolute risk reduction shrinks while drug cost stays fixed.

Sequential Therapy Assumptions

The ARCH protocol transitioned all patients to alendronate after the romosozumab or placebo phase. Economic models that assume romosozumab followed by denosumab rather than a bisphosphonate generate different cost estimates. Leder et al. (2015) and subsequent data show that anti-resorptive consolidation preserves the bone density gains from anabolic therapy, but denosumab adds ongoing biologic cost. Most models use the alendronate sequence to match the trial design.

Fracture Cost Inputs

US models typically assign $40,000 to $60,000 for the first-year cost of a hip fracture (acute care, rehabilitation, nursing facility). Burge et al. (2007) estimated total US osteoporotic fracture costs at $19 billion annually. Higher per-fracture cost estimates improve romosozumab's ICER because each avoided fracture offsets more drug expense.

Time Horizon and Discount Rate

A lifetime horizon (age 74 to death) captures more fracture events than a 5- or 10-year window, which favors romosozumab. A higher discount rate (5% vs. 3%) penalizes the intervention because the drug cost is upfront while fracture savings accrue over decades. Most published models use 3% annual discounting per US Panel on Cost-Effectiveness guidelines.

Payer Coverage in Practice

Despite ICER estimates near the $100,000 to $150,000/QALY threshold, real-world payer coverage for romosozumab remains inconsistent. Most US commercial plans and Medicare Part B (romosozumab is a physician-administered injectable) cover the drug with prior authorization requirements that typically mandate documented T-score at or below -2.5, prior fracture or failed bisphosphonate therapy, and no history of recent myocardial infarction or stroke.

The Evenity label carries a boxed warning for cardiovascular risk based on a numerical imbalance in the ARCH trial: 2.5% of romosozumab patients experienced a major adverse cardiac event versus 1.9% in the alendronate group. This finding, while not statistically definitive, gave payers a rationale for step-therapy requirements and cardiologist clearance mandates that slow uptake. The Endocrine Society 2020 guidelines recommend romosozumab for patients at very high fracture risk but advise cardiovascular risk assessment before prescribing.

The Individual Patient Value Calculation

For a clinician and patient sitting across from each other, the population-level ICER is informative but not sufficient. The practical question is whether the incremental fracture prevention justifies the copay burden, injection visits, and cardiovascular monitoring for this specific patient.

A 75-year-old woman with a T-score of -3.2, two prior vertebral fractures, and no cardiovascular history closely matches the ARCH population where the absolute risk reduction was largest. Her number needed to treat (NNT) to prevent one vertebral fracture over 24 months was approximately 12 in the trial. If her Medicare Part B copay for romosozumab is roughly $4,500 (20% coinsurance on the allowed amount), and avoiding a vertebral fracture saves her an expected $12,000 to $25,000 in medical costs plus preserved quality of life, the individual calculus can favor treatment.

By contrast, a 65-year-old woman with a T-score of -2.5 and no prior fracture faces a much higher NNT and a longer time until expected benefit. For her, starting with a bisphosphonate per AACE 2020 guidelines and reserving romosozumab for inadequate response is more economically rational.

Limitations of Current Economic Evidence

Every published model relies on the same ARCH dataset for efficacy inputs. There are no independent replication trials comparing romosozumab to an active bisphosphonate. The FRAME trial used placebo as comparator and enrolled lower-risk women, so its data cannot substitute for ARCH in economic modeling of the high-risk population.

Model-specific limitations include uncertainty around long-term fracture efficacy beyond the trial's 33-month median follow-up, reliance on assumptions about treatment persistence (real-world adherence to monthly injections is lower than trial adherence), and incomplete capture of indirect costs such as caregiver burden and lost productivity.

The cardiovascular signal remains unresolved. If future data confirm a causal link between romosozumab and cardiovascular events, economic models would need to incorporate the cost of those events on the debit side, shifting ICERs unfavorably.

Frequently asked questions

›

References

Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417-1427. PubMed
Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D. Cost effectiveness of romosozumab vs alendronate for osteoporosis in the US. J Med Econ. 2019;22(7):621-631. PubMed
Söreskog E, Lindqvist K, Engström G, Ström O. Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Sweden. Osteoporos Int. 2021;32(3):585-594. PubMed
Evenity (romosozumab-aqqg) prescribing information. Amgen Inc. 2019. FDA Label
Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2020;26(Suppl 1):1-46. PubMed
Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. PubMed